Shares of the leading pharma company Glenmark Pharmaceuticals in Monday's (February 17) ) early morning deals gained 6 per cent at the day's high to Rs 1,399.15 apiece on the BSE. The gains in the stock were triggered post the company's largely in-line December quarter results.

At around 11 am, shares of Glenmark Pharma were up 4.49 per cent or Rs 59.3 at Rs 1,380.65 apiece on the BSE.

For the December quarter of the ongoing fiscal year FY2024-25, the pharma major reported a profit of Rs 348 crore as against a net loss of Rs 470.1 crore during the same period of the previous year. Zee Business research estimated the company to report Rs 350 crore in profit for the review quarter.

The revenue from operations at the concern also marked a 35.1 per cent year-on-year (YoY) rise to Rs 3,387.6 crore, coming in higher-than-estimates of Rs 3,350 crore. Revenue in the corresponding period of the previous year stood at Rs 2,506.7 crore. Further, the EBITDA margin came in at 17.7 per cent as against estimates of 17.9 per cent.

India 

Sales from the formulation business in India in Q3 FY 2025 was at Rs 1063.7 crore as against Rs 2,65.8 crore in the previous corresponding quarter, recording growth of 300.2 per cent YoY.

North America

North America registered revenue from the sales of finished dosage formulations of Rs. 781.3 crore for the quarter ended Dec 31, 2024 as against revenue of Rs. 770.5 crore for the previous corresponding quarter, recording growth of 1.4 per cent YoY.

Asia, MEA, LATAM and RCIS Region (RoW)

For the third quarter of FY 2025, revenue from RoW was Rs. 749.1 crore as against Rs 727.1 crore for the previous corresponding quarter, recording growth of 3 per cent YoY. The reported growth for the ROW region during the quarter was impacted due to the adverse currency movements in some of the key markets.

Europe

Glenmark Europe’s operations revenue for the third quarter of FY 2025, was at Rs. 729.7 crore as against Rs. 635.7 crore, and recording growth of 14.8 per cent YoY.